Differences in Treatment Outcomes Between Patients with HER2-Low versus HER2-Zero, Hormone Receptor-Positive Advanced-Stage Breast Cancer Treated with Ribociclib.

23 Another Greek multicenter study reported real-world data testing the same concept on 191 patients and showed worsening PFS with increasing HER2 expression; 3.35 years for HER2-zero patients, 2.18 years for HER2 +1 patients, and 1.74 years for HER2 +2/ISH-negative patients; however, this difference did not reach statistical significance (p = 0.477). 24 However, another Italian study from six oncology units reached a different conclusion.

also in 111,027 other papers